Abingdon Health Plc
ABDXF · OTC
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | $4 | $4 | $1 | $3 |
| % Growth | 3.9% | 209.1% | -58.9% | – |
| Cost of Goods Sold | $2 | $1 | $1 | $1 |
| Gross Profit | $1 | $2 | -$0 | $1 |
| % Margin | 30.6% | 64.5% | -17.6% | 49.2% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $3 | $2 | $1 | $1 |
| SG&A Expenses | $3 | $2 | $3 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $1 | $1 |
| Other Operating Expenses | $1 | $0 | $0 | $0 |
| Operating Expenses | $4 | $3 | $3 | $3 |
| Operating Income | -$3 | -$0 | -$2 | -$1 |
| % Margin | -68.2% | -4.3% | -144.8% | -42.1% |
| Other Income/Exp. Net | $0 | -$0 | $1 | $1 |
| Pre-Tax Income | -$3 | -$0 | -$1 | -$1 |
| Tax Expense | -$0 | -$0 | -$0 | -$0 |
| Net Income | -$3 | -$0 | -$1 | -$1 |
| % Margin | -81.5% | -1.8% | -100% | -35.1% |
| EPS | -0.007 | -0 | -0.002 | -0.003 |
| % Growth | -3,450% | 90% | 41.2% | – |
| EPS Diluted | -0.007 | -0 | -0.002 | -0.003 |
| Weighted Avg Shares Out | 355 | 306 | 301 | 304 |
| Weighted Avg Shares Out Dil | 355 | 305 | 304 | 304 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$2 | -$0 | -$0 | -$0 |
| % Margin | -50.7% | -0% | -37.1% | -6.4% |